Location Directory

Clinical trials in Indianapolis, Indiana

This page shows live ClinicalTrials.gov search results for Indianapolis, Indiana, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

8604

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Aortic Stenosis Treated With TAVI, Aortic Diseases
Interventions: F2 Filter and Delivery System, Transcatheter Aortic Valve Replacement (TAVR); Device · Procedure
Lead sponsor: EnCompass Technologies, Inc.; Industry
Eligibility: 21 Years to 90 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: Naples, Florida • Indianapolis, Indiana • Detroit, Michigan + 5 more

Conditions: Genetic Disease
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 1 Month to 100 Years
Enrollment: 20,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2099
U.S. locations: 33
States / cities: Birmingham, Alabama • Huntsville, Alabama • Los Angeles, California + 21 more

Conditions: Thrombocytopenia, Neonatal Alloimmune
Interventions: Nipocalimab, Intravenous immunoglobulins (IVIG), Prednisone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 13
States / cities: Birmingham, Alabama • Sacramento, California • Aurora, Colorado + 10 more

Conditions: Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Echocardiography Test, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Observation Activity, Paclitaxel, Pembrolizumab, Pemetrexed Disodium, Questionnaire Administration; Procedure · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1,210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1150
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 747 more

Conditions: Hidradenitis Suppurativa (HS)
Interventions: povorcitinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 94
States / cities: Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 72 more

Conditions: Low Grade Astrocytoma, Low Grade Glioma, Metastatic Low Grade Astrocytoma, Metastatic Low Grade Glioma, WHO Grade 1 Glioma, WHO Grade 2 Glioma
Interventions: Biospecimen Collection, Carboplatin, Echocardiography Test, Magnetic Resonance Imaging, Questionnaire Administration, Selumetinib Sulfate, Vincristine Sulfate; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 21 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 124
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 101 more

Conditions: Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
Interventions: Biospecimen Collection, cfDNA or ctDNA Measurement, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Nivolumab, Questionnaire Administration, Relatlimab; Procedure · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 992 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 495
States / cities: Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 374 more

Conditions: Denture Retention
Interventions: Experimental Denture Adhesive 1, Experimental Denture Adhesive 2, Experimental Denture Adhesive 3, Poligrip Power Hold + Seal; Device
Lead sponsor: HALEON; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Traumatic Brain Injury
Interventions: Blood draw, Outcome assessments; Diagnostic Test · Other
Lead sponsor: Abbott Point of Care; Industry
Eligibility: 18 Years and older
Enrollment: 1,106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 21
States / cities: San Francisco, California • Denver, Colorado • Englewood, Colorado + 17 more

Conditions: Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features
Interventions: Biospecimen Collection, Computed Tomography, Mosunetuzumab, Positron Emission Tomography, Rituximab, Rituximab and Hyaluronidase Human; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 288
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 229 more

Conditions: Endometrial Cancer
Interventions: Selinexor, Matching Placebo for selinexor; Drug
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 65
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 55 more

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
Interventions: Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Liposome-encapsulated Daunorubicin-Cytarabine, Multigated Acquisition Scan, Venetoclax; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 59 Years
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 216
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 175 more

Clinical trials in Indianapolis, Indiana

Filter and sort this location

Live official records

Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR

Clinical and Genetic Evaluation of Individuals With Undiagnosed Disorders Through the Undiagnosed Diseases Network

A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

A Clinical Study to Assess the Effectiveness of Use of Three Experimental Denture Adhesives Compared to Using No-Adhesive

Clinical Evaluation of the i-STAT TBI Test

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)